AIM ImmunoTech Announces Stock Dividend
MWN-AI** Summary
AIM ImmunoTech Inc. (NYSE American: AIM) announced a stock dividend on December 30, 2025, distributing one share of common stock for every 1,000 shares held, as well as one share for each outstanding option or warrant eligible for stock dividends. This dividend will be allocated to stockholders and holders of alternate securities recorded at the close of business on January 9, 2026. The shares will be distributed through the Depository Trust & Clearing Corporation (DTCC) on January 13, 2026. Any fractional shares resulting from this distribution will be rounded down, with cash payments issued for those fractions based on an average share price of $1.305, representing the average high and low share prices on December 29, 2025.
Stockholders will not need to take action as their accounts will automatically be credited with the additional shares following the payment date. Shares held in brokerage accounts will be distributed by brokers on behalf of the stockholders, overseen by EQ, AIM's transfer agent.
AIM ImmunoTech focuses on developing therapeutics for various cancers, immune disorders, and viral diseases, including COVID-19, with its leading investigational product, Ampligen® (rintatolimod), already in clinical trials for significant health issues worldwide.
The announcement includes cautionary remarks about forward-looking statements, emphasizing that past clinical successes do not guarantee approval for Ampligen for any therapeutic indication. Investors are warned of inherent risks and are encouraged to review AIM's latest filings with the SEC for comprehensive risk factors.
For further details, AIM encourages visiting their website and connecting via social media platforms.
MWN-AI** Analysis
AIM ImmunoTech Inc. (NYSE American: AIM) is making waves with its recent announcement of a stock dividend—a notable move that investors should analyze closely. The company has declared a dividend of one share of common stock for every 1,000 shares held, along with shares for outstanding options or warrants. The effective date for determining stockholders eligible for this dividend will be January 9, 2026, with distribution occurring shortly thereafter on January 13, 2026.
Such a stock dividend typically signals the company's commitment to returning value to its shareholders, and it can be interpreted in multiple ways. While it’s not a cash dividend, the issuance of additional shares can serve to enhance liquidity and potentially attract new investors who view the stock as more favorable due to the perceived increase in their holdings.
Nonetheless, this move may also dilute existing shares, which is a crucial consideration for current investors. The dividend ratio indicates that for every 1,000 shares owned, shareholders will receive just one additional share, which is a modest return that may not significantly impact the stock’s overall value. Hence, potential investors should weigh this dividend against the company’s ongoing projects and clinical trials, particularly its lead drug, Ampligen®, which is still in investigational phases.
Investors should keep in mind the inherent risks and uncertainties associated with AIM’s developments. Clinical success does not guarantee market approval, and the market may react unpredictably. As always, it would be prudent for investors to review AIM’s latest filings with the SEC to gauge its financial health and risk factors before making any investment decisions. Balancing optimism for the company’s innovative potential against the realities of its operational challenges will be key going forward.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
OCALA, Fla., Dec. 30, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced a stock dividend of one share of common stock for every 1,000 shares of outstanding common stock as well as one share of common stock for every outstanding option or warrant that has a right to receive stock dividends (“Alternate Securities”). The dividend will be issuable to stockholders and Alternate Securities holders of record at the close of business on January 9, 2026 and will be distributed and allocated to DTCC on January 13, 2026.
Resulting fractional shares will be rounded down and any resulting fractional shares remaining after the foregoing rounding down will be distributed cash to each stockholder and Alternate Securities holder who would otherwise have been entitled to receive such fractional shares, based on a share price of $1.305, which is the average of the high and low share price on December 29, 2025.
Stockholders will not be required to take any action to receive the stock dividend. After the payment date, stockholders' book entry accounts will be credited with the additional shares that represent the stock dividend. Where shares are held in a brokerage account in the name of a broker, the additional shares will be distributed to the broker on the stockholder's behalf. The stock dividend is administered by EQ, the Company's transfer agent.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.
For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.
Cautionary Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “continue,” “believe,” “potential,” “upcoming” and other variations thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. Data, pre-clinical success and clinical success seen to date do not guarantee that Ampligen will be approved as a therapy for any indication. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Among other things, for those statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.
Investor Contact:JTC Team, LLCJenene Thomas908.824.0775AIM@jtcir.com
FAQ**
How does AIM ImmunoTech Inc.'s stock dividend of one share per 1,000 shares outstanding exemplify its commitment to enhancing shareholder value, and what implications might this have for future investor interest in AIM ImmunoTech Inc. AIM?
In light of the stock dividend announcement, what strategies does AIM ImmunoTech Inc. AIM plan to implement to ensure that their lead product Ampligen® gains regulatory approval and reaches the market successfully?
Considering the diverse therapeutic areas AIM ImmunoTech Inc. AIM is targeting, including cancers and viral diseases, how does the company's research align with current market trends and investor expectations?
What potential risks and uncertainties should investors be aware of regarding AIM ImmunoTech Inc. AIM’s forward-looking statements, particularly those related to Ampligen® and its clinical development?
**MWN-AI FAQ is based on asking OpenAI questions about AIM ImmunoTech Inc. (NYSE: AIM).
NASDAQ: AIM
AIM Trading
0.87% G/L:
$0.6872 Last:
36,840 Volume:
$0.70 Open:
